310 related articles for article (PubMed ID: 31669559)
1. Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies.
Scialdone A; Khazaei S; Hasni MS; Lennartsson A; Gullberg U; Drott K
Exp Hematol; 2019 Nov; 79():35-46.e1. PubMed ID: 31669559
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
[TBL] [Abstract][Full Text] [Related]
3. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20.
Guan XW; Wang HQ; Ban WW; Chang Z; Chen HZ; Jia L; Liu FT
Cell Death Dis; 2020 Jan; 11(1):20. PubMed ID: 31907371
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.
Winiarska M; Bojarczuk K; Pyrzynska B; Bil J; Siernicka M; Dwojak M; Bobrowicz M; Miazek N; Zapala P; Zagozdzon A; Krol M; Syta A; Podszywalow-Bartnicka P; Pilch Z; Dabrowska-Iwanicka A; Juszczynski P; Efremov DG; Slabicki M; Zenz T; Le Roy A; Olive D; Rygiel TP; Leusen JH; Golab J
MAbs; 2014; 6(5):1300-13. PubMed ID: 25517315
[TBL] [Abstract][Full Text] [Related]
5. De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity.
Tokunaga T; Tomita A; Sugimoto K; Shimada K; Iriyama C; Hirose T; Shirahata-Adachi M; Suzuki Y; Mizuno H; Kiyoi H; Asano N; Nakamura S; Kinoshita T; Naoe T
Cancer Sci; 2014 Jan; 105(1):35-43. PubMed ID: 24147568
[TBL] [Abstract][Full Text] [Related]
6. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
Front Immunol; 2020; 11():609941. PubMed ID: 33505398
[TBL] [Abstract][Full Text] [Related]
7. Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach.
de Jong MRW; Visser L; Huls G; Diepstra A; van Vugt M; Ammatuna E; van Rijn RS; Vellenga E; van den Berg A; Fehrmann RSN; van Meerten T
PLoS One; 2018; 13(2):e0193098. PubMed ID: 29489886
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation.
Hayashi K; Nagasaki E; Kan S; Ito M; Kamata Y; Homma S; Aiba K
Cancer Sci; 2016 May; 107(5):682-9. PubMed ID: 26920337
[TBL] [Abstract][Full Text] [Related]
9. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL.
Awasthi A; Ayello J; Van de Ven C; Elmacken M; Sabulski A; Barth MJ; Czuczman MS; Islam H; Klein C; Cairo MS
Br J Haematol; 2015 Dec; 171(5):763-75. PubMed ID: 26471982
[TBL] [Abstract][Full Text] [Related]
10. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
11. Determination of optimum vitamin D3 levels for NK cell-mediated rituximab- and obinutuzumab-dependent cellular cytotoxicity.
Neumann F; Acker F; Schormann C; Pfreundschuh M; Bittenbring JT
Cancer Immunol Immunother; 2018 Nov; 67(11):1709-1718. PubMed ID: 30132083
[TBL] [Abstract][Full Text] [Related]
12. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
[TBL] [Abstract][Full Text] [Related]
13. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.
Shimizu R; Kikuchi J; Wada T; Ozawa K; Kano Y; Furukawa Y
Leukemia; 2010 Oct; 24(10):1760-8. PubMed ID: 20686505
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab.
Yasuhiro T; Sawada W; Klein C; Kozaki R; Hotta S; Yoshizawa T
Leuk Lymphoma; 2017 Mar; 58(3):699-707. PubMed ID: 27684575
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphoma.
Nie M; Du L; Ren W; Joung J; Ye X; Shi X; Ciftci S; Liu D; Wu K; Zhang F; Pan-Hammarström Q
Cell Death Dis; 2021 Apr; 12(5):419. PubMed ID: 33911074
[TBL] [Abstract][Full Text] [Related]
16. CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas.
Veazey KJ; Cheng D; Lin K; Villarreal OD; Gao G; Perez-Oquendo M; Van HT; Stratton SA; Green M; Xu H; Lu Y; Bedford MT; Santos MA
Leukemia; 2020 Dec; 34(12):3269-3285. PubMed ID: 32576962
[TBL] [Abstract][Full Text] [Related]
17. Pyruvate dehydrogenase kinase 4-mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B-cell lymphoma by affecting the expression of MS4A1/CD20.
Jiang D; Mo Q; Sun X; Wang X; Dong M; Zhang G; Chen F; Zhao Q
Cancer Sci; 2021 Sep; 112(9):3585-3597. PubMed ID: 34252986
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma.
Heinrich DA; Weinkauf M; Hutter G; Zimmermann Y; Jurinovic V; Hiddemann W; Dreyling M
Br J Haematol; 2015 Feb; 168(4):606-10. PubMed ID: 25292485
[No Abstract] [Full Text] [Related]
19. Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma.
Meyer SN; Scuoppo C; Vlasevska S; Bal E; Holmes AB; Holloman M; Garcia-Ibanez L; Nataraj S; Duval R; Vantrimpont T; Basso K; Brooks N; Dalla-Favera R; Pasqualucci L
Immunity; 2019 Sep; 51(3):535-547.e9. PubMed ID: 31519498
[TBL] [Abstract][Full Text] [Related]
20. Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance.
Tomita A
J Clin Exp Hematop; 2016; 56(2):89-99. PubMed ID: 27980307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]